These three nonprofits are making a difference where it’s needed the most.
News & Analysis: Bristol Myers Squibb
These three companies have the resources and the positioning to survive the harshest of economic conditions.
Sometimes, simple things like reliable income just make more sense.
Here's how these two drugmakers stack up against each other.
These drugmakers' businesses shouldn't be significantly impacted by an economic downturn.
Here's why this cheap blue-chip pharma stock is a solid buy for dividend, value, and growth investors alike.
They're not nearly as fun to talk about at cocktail parties, but these proven workhorses are still very affordable picks.
Neither drugmaker has been a winner this year. But one appears to be a pretty safe bet to win in the future.
This healthcare stock could be a gamechanger for long-term investors who buy in today.
Growth? Value? Income? There are great deals available for all types of long-term investors.